ACADIA PHARMACEUTICALS INC

Acadia Pharmaceuticals insider sale: Kihara James sells 11,421 shares at $26.08, a planned 10b5‑1 trade amid rising EMA buzz and rising investor interest.

Insider buys and RSUs signal confidence in Acadia’s CNS pipeline, suggesting a 2026‑2027 upside as Parkinson’s and schizophrenia trials mature.

Insider sales at ACADIA reveal no major valuation shifts—focus on pipeline milestones, regulatory progress and market access instead.

Acadia Pharmaceuticals’ insider buying signals confidence in its CNS drug pipeline and upcoming FDA review, offering investors a bullish outlook amid solid valuation metrics.

CEO’s ACADIA insider moves: zero‑cost stock buys and RSU sales reveal confidence amid a 3.57% weekly price rise, signaling strategic liquidity and long‑term ownership.

Acadia CFO’s recent insider trades reveal confidence in its late‑stage Parkinson’s and schizophrenia pipeline, RSU‑driven growth strategy, and analyst‑backed market‑access upside.

ACADIA insider Jennifer Rhodes buys 12,944 shares via RSUs, boosting her stake and signaling confidence ahead of Feb 25 earnings and CNS pipeline progress.